相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients
Francesca Gay et al.
BLOOD (2010)
Arterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based study
Sigurdur Y. Kristinsson et al.
BLOOD (2010)
High incidence of arterial thrombosis in young patients treated for multiple myeloma: results of a prospective cohort study
Eduard J. Libourel et al.
BLOOD (2010)
Survival Effect of Venous Thromboembolism in Patients With Multiple Myeloma Treated With Lenalidomide and High-Dose Dexamethasone
Maurizio Zangari et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
New aspects on treatment modalities for thromboembolic episodes
S. Schulman
JOURNAL OF INTERNAL MEDICINE (2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone
Ulrike Klein et al.
ANNALS OF HEMATOLOGY (2009)
Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study
Ola Landgren et al.
BLOOD (2009)
Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias
Charles Eby
BRITISH JOURNAL OF HAEMATOLOGY (2009)
AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS CLINICAL PRACTICE GUIDELINE ON Prevention of Symptomatic Pulmonary Embolism in Patients Undergoing Total Hip or Knee Arthroplasty
Norman A. Johanson et al.
JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME (2009)
Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial
Cyrille Hulin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Venous Thromboembolism in the Hematologic Malignancies
Anna Falanga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma
Sigurdur Y. Kristinsson et al.
BLOOD (2008)
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Michael Wang et al.
BLOOD (2008)
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
David C. Johnson et al.
BLOOD (2008)
Prevention of venous thromboembolism
William H. Geerts et al.
CHEST (2008)
Testing for inherited thrombophilia does not reduce the recurrence of venous thrombosis
M. Coppens et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens
Adriana M. W. van Marion et al.
LEUKEMIA RESEARCH (2008)
Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro
Ferit Avcu et al.
THROMBOSIS RESEARCH (2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
A. Palumbo et al.
LEUKEMIA (2008)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Meletios Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America
Donna M. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial
Thierry Facon et al.
LANCET (2007)
Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients
Maurizio Zangari et al.
BLOOD COAGULATION & FIBRINOLYSIS (2007)
Thalidomide causes platelet activation, which can be abrogated by aspirin
S. Dunkley et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2007)
Patterns of survival in multiple myeloma:: A population-based study of patients diagnosed in Sweden from 1973 to 2003
Sigurdur Yngvi Kristinsson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients
Gareth J. Morgan et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma
Ruben Niesvizky et al.
LEUKEMIA & LYMPHOMA (2007)
Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy
R. Baz et al.
ANNALS OF ONCOLOGY (2006)
The combination of cyclophosphomide, thalidomide and dexamethasone is an effective alternative to cyclophosphamide-vincristine-doxorubicin-methylprednisolone as induction chemotherapy prior to autologous transplantation for multiple myeloma: a case-matched analysis
Ping Wu et al.
LEUKEMIA & LYMPHOMA (2006)
Thalidomide, dexamethasone, and pegylated liposomal doxorubicin (ThaDD) for patients older than 65 years with newly diagnosed multiple myelorna
Massimo Offidani et al.
BLOOD (2006)
Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism
Francesca Elice et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis
JA Zonder et al.
BLOOD (2006)
Efficacy of prophylactic warfarin for prevention of thalidomide-related deep venous thrombosis
Nadeem Ikhlaque et al.
AMERICAN JOURNAL OF HEMATOLOGY (2006)
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled-trial
A Palumbo et al.
LANCET (2006)
Thalidomide and hematopoietic-cell transplantation for multiple myeloma
B Barlogie et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the eastern cooperative oncology group
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
SV Rajkumar et al.
BLOOD (2005)
The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma
R Baz et al.
MAYO CLINIC PROCEEDINGS (2005)
A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma
HM Prince et al.
CLINICAL CANCER RESEARCH (2005)
Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma
M Wang et al.
AMERICAN JOURNAL OF HEMATOLOGY (2005)
Safety of low-dose low-molecular-weight-heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature
RB Ibrahim et al.
BONE MARROW TRANSPLANTATION (2005)
Regulation of endothelial thrombomodulin expression by inflammatory cytokines is mediated by activation of nuclear factor-kappa B
RH Sohn et al.
BLOOD (2005)
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation
M Zangari et al.
BRITISH JOURNAL OF HAEMATOLOGY (2004)
Prevention of venous thromboembolism with low molecular-weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy
MC Minnema et al.
LEUKEMIA (2004)
Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): a phase II multicenter study
K Zervas et al.
ANNALS OF ONCOLOGY (2004)
Thalidomide plus oral melphalan compared with thalidomide alone for advanced multiple myeloma
M Offidani et al.
HEMATOLOGY JOURNAL (2004)
Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma
A Palumbo et al.
HEMATOLOGY JOURNAL (2004)
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer
AYY Lee et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Thalidomide as initial therapy for early-stage myeloma
SV Rajkumar et al.
LEUKEMIA (2003)
Thalidomide alone or with dexamethasone for previously untreated multiple myeloma
D Weber et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism
P Prandoni et al.
ANNALS OF INTERNAL MEDICINE (2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
PG Richardson et al.
BLOOD (2002)
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma
SV Rajkumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy
M Zangari et al.
BLOOD (2002)
Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients
B Barlogie et al.
BLOOD (2001)
Deep venous thrombosis and thalidomide therapy for multiple myeloma.
K Osman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Risk factors for deep vein thrombosis and pulmonary embolism -: A population-based case-control study
JA Heit et al.
ARCHIVES OF INTERNAL MEDICINE (2000)
分享论文
